JPH01232972A - Blood filter - Google Patents

Blood filter

Info

Publication number
JPH01232972A
JPH01232972A JP63059174A JP5917488A JPH01232972A JP H01232972 A JPH01232972 A JP H01232972A JP 63059174 A JP63059174 A JP 63059174A JP 5917488 A JP5917488 A JP 5917488A JP H01232972 A JPH01232972 A JP H01232972A
Authority
JP
Japan
Prior art keywords
cross
section
surface area
rate
fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63059174A
Other languages
Japanese (ja)
Other versions
JP2906409B2 (en
Inventor
Akira Hosokawa
朗 細川
Akira Yagi
晃 八木
Hideo Isoda
英夫 磯田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP63059174A priority Critical patent/JP2906409B2/en
Priority to IT8919741A priority patent/IT1228361B/en
Publication of JPH01232972A publication Critical patent/JPH01232972A/en
Application granted granted Critical
Publication of JP2906409B2 publication Critical patent/JP2906409B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Filtering Materials (AREA)
  • External Artificial Organs (AREA)

Abstract

PURPOSE:To reduce the damage of blood corpuscles and to make a leucocyte removing rate and an erythrocyte recovery rate excellent, by constituting a filter of nonwoven fabric using a synthetic fiber having predetermined monofilament fineness and a profile cross-section whose surface area increase rate is a specific value or more. CONSTITUTION:The fineness of the monofilament of a synthetic fiber constituting a blood filter is set to 0.25 denier or less, pref., to 0.1 denier or less and the cross-section of the monofilament has an odd-shape and the surface area increase ratio F=l/(4pis)1/2(wherein l is the average outer peripheral length of the monofilament cross-section and s is the average cross-section of the monofilament cross-section) is 1.15 or more. This synthetic fiber is in an opened state. Since the synthetic fiber constituting the blood filter has the profile cross-section, an increasing surface area increase ratio is 1.15 or more, pref., 1.30 or more as compared with a round cross-sectional fiber and the surface area increase ratio of 1.15 or less is not pref. because the enhancement of the removal rate of a leucocyte is less as compared with the round cross-sectional fiber. By this method, even when the diameter of a fiber is not made too small and a filling rate is not enhanced, the contact surface area of the fiber with a leucocyte is increased, and a leucocyte removing rate and an erythrocyte recovery rate are made excellent.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は血液フィルター、ことに白血球を含む体液、リ
ンパ液やそれらの処理から白血球を除去するためにフィ
ルターに関し、詳細には構成繊維のサイズ・形状特性及
び構造を特定することによって、血球損傷の少ない白血
球除去率並びに赤血球回収率に優れた白血球除去フィル
ターに関する。
Detailed Description of the Invention (Industrial Application Field) The present invention relates to a blood filter, and particularly to a filter for removing white blood cells from body fluids containing white blood cells, lymph fluid, and their processing. The present invention relates to a leukocyte removal filter that causes less blood cell damage and has an excellent leukocyte removal rate and red blood cell recovery rate by specifying the shape characteristics and structure.

(従来の技術) 輸血に関する最近の考え方は、従来の全血軸から患者の
必要に応じた成分に移行している。即ち従来の全血輸血
や赤血球濃度液輸血では、これらを輸血された患者に組
織適合性抗原不都合による発熱、頭痛、吐き気等の副作
用を起こす場合が多い。従って赤血球のみを必要とする
一般の輸血には余分な成分はできるだけ含まず赤血球の
みを含有する血液の輸血を行う方がよいと考えられる様
になってきている。
(Prior Art) Recent thinking regarding blood transfusion has shifted from the traditional whole blood axis to components tailored to the needs of the patient. That is, conventional whole blood transfusions and red blood cell concentration fluid transfusions often cause side effects such as fever, headache, and nausea due to the inconvenience of histocompatibility antigens in patients receiving these transfusions. Therefore, for general blood transfusions that only require red blood cells, it has come to be considered that it is better to transfuse blood that contains only red blood cells and contains as few extra components as possible.

全血から白血球を除去する方法は遠心法、デキストラン
沈降法、フィルター法に大別されるが、操作の簡便さや
低コストの面からフィルター法が主体となった検討が進
められている。フィルター法は繊維素材や充填方法の検
討、特に繊維径や充填率で白血球除去性、分離効率を上
げる努力がなされており、例えば特公昭58−5412
5において繊維径を小さくし、充填率を上げることによ
って白血球と接触する繊維表面が増し、白血球除去率が
良くなることが知られている。
Methods for removing leukocytes from whole blood are broadly classified into centrifugation, dextran sedimentation, and filter methods, but the filter method is currently being studied primarily due to its ease of operation and low cost. Regarding the filter method, efforts have been made to improve leukocyte removal performance and separation efficiency by examining fiber materials and filling methods, especially by adjusting fiber diameter and filling rate.
It is known that by decreasing the fiber diameter and increasing the filling rate in No. 5, the fiber surface that comes into contact with leukocytes increases and the leukocyte removal rate improves.

しかしながら、繊維径はある程度までしか小さくするこ
とは困難であり、また充填率を上げると白血球がつまり
短時間で除去率が低下する。
However, it is difficult to reduce the fiber diameter only to a certain extent, and when the filling rate is increased, white blood cells become clogged and the removal rate decreases in a short period of time.

(発明が解決しようとする課題) 本発明は、上記のような問題点に着目してなされたもの
である。すなわち繊維径をあまり小さくせず、また充填
率を上げなくても白血球と接触する繊維表面積を増加さ
せ、白血球除去率並びに赤血球回収率に優れた白血球フ
ィルターを提供することを目的とするものである。
(Problems to be Solved by the Invention) The present invention has been made by focusing on the above-mentioned problems. In other words, the object is to increase the surface area of the fibers in contact with leukocytes without reducing the fiber diameter too much or increasing the filling rate, and to provide a leukocyte filter with excellent leukocyte removal rate and red blood cell recovery rate. .

(課題を解決するための手段) 本発明は、単繊維繊度が0.25デニール以下で、下記
式で示される表面積増加比Fが1.15以上の異形断面
を有する合成繊維を用いた不織布で構成されることを特
徴とする血液フィルターである。
(Means for Solving the Problems) The present invention provides a nonwoven fabric using synthetic fibers having a single fiber fineness of 0.25 denier or less and a modified cross section having a surface area increase ratio F of 1.15 or more as expressed by the following formula. A blood filter characterized in that:

本発明でいうフィルターとは異形断面繊維で構成される
不織布状シートが単層または複数層積層されたものをい
う。
The term "filter" used in the present invention refers to a single layer or a multi-layered nonwoven sheet made of fibers with irregular cross sections.

本発明にかかる血液フィルターを構成する合成繊維の単
繊維の繊度は0.25デニール以下好ましくは0.1デ
ニール以下でなければならず、且つ単繊維断面は異形を
有し表面積増加比が1.15以上である。かかる合成繊
維は開繊された状態であることを特徴とし、これにより
繊維の表面積が増し白血球除去率並びに赤血球回収率に
優れた白血球除去効果を発現する。
The fineness of the single fibers of the synthetic fibers constituting the blood filter according to the present invention must be 0.25 denier or less, preferably 0.1 denier or less, and the cross section of the single fibers has an irregular shape and a surface area increase ratio of 1. 15 or more. Such synthetic fibers are characterized by being in an opened state, which increases the surface area of the fibers and exhibits a leukocyte removal effect with excellent leukocyte removal rate and red blood cell recovery rate.

本発明にかかる血液フィルターを構成する合成繊維の繊
度が025デニ一ル以上になると、白血球との接触面積
が低下し、白血球除去性が劣ると共に異形断面効果によ
りドレープ性、ソフトさも劣るので好ましくない。繊度
か細くなり過ぎると構造体を構成する単繊維自体が、弱
い力で用意に変形を生じやすくするため、好ましい繊度
は0.05デニールから0.005デニールである。
If the fineness of the synthetic fibers constituting the blood filter of the present invention exceeds 0.025 denier, it is not preferable because the contact area with white blood cells decreases, leukocyte removal performance is poor, and drapability and softness are also poor due to the irregular cross-sectional effect. . If the fineness is too fine, the single fibers forming the structure are easily deformed by weak force, so the preferable fineness is from 0.05 denier to 0.005 denier.

本発明にかかる血液フィルターを構成する合成繊維の断
面は、異形断面化されていることにより、丸断面繊維に
比べて、増加する表面積増加率が1.15以上好ましく
は1.30以上であり1.15より少ない表面積増加比
では、丸断面繊維に比べ白血球除去率の向上が少ないの
で好ましくない。ここで表面積増加比は、大きければ大
きいほど好ましいが、製造の面より10程度が限界と推
測される。合成繊維の断面形状は特に限定されない。
The cross section of the synthetic fibers constituting the blood filter of the present invention has a modified cross section, so that the surface area increase rate is 1.15 or more, preferably 1.30 or more, compared to round cross section fibers. A surface area increase ratio of less than .15 is not preferred because the leukocyte removal rate is less improved than with round cross-section fibers. Here, the larger the surface area increase ratio is, the more preferable it is, but from the viewpoint of manufacturing, it is estimated that about 10 is the limit. The cross-sectional shape of the synthetic fiber is not particularly limited.

本発明にかる血液フィルターを構成する合成繊維はポリ
エステル、ポリアミド、ポリオレフィン、ポリアクリル
ニトリル、ポリ塩化ビニル等溶融紡糸が可能な合成高分
子であれば、特に限定されないが好ましくはポリエステ
ル、ポリアミド、全芳香族高分子などの比較的高モジュ
ラスか、耐熱性、耐薬品性、耐候性などの特性が付与で
きるものが例示される。
The synthetic fibers constituting the blood filter of the present invention are not particularly limited as long as they are synthetic polymers that can be melt-spun, such as polyester, polyamide, polyolefin, polyacrylonitrile, polyvinyl chloride, etc., but preferably polyester, polyamide, fully aromatic fibers, etc. Examples include polymers with relatively high modulus such as group polymers, and those that can provide properties such as heat resistance, chemical resistance, and weather resistance.

本発明のフィルターを構成する不織布の嵩填密度は0.
05〜0.5 g/cIi1、好ましくは0. 1〜0
.3g/CTa、目イ=tt O−100g/cJテア
ッて該不織布が単層または複数層積層されたものである
The bulk density of the nonwoven fabric constituting the filter of the present invention is 0.
05-0.5 g/cIi1, preferably 0. 1~0
.. 3g/CTa, eye = tt O-100g/cJ The nonwoven fabric is a single layer or multiple layers laminated.

実施例1 第1図に示すメルトブローノズル(図中1はオリフィス
孔、4は過度検出端を示す)を用いて、極限粘度0.6
5のポリエチレンテレフタレートをオリフィス孔相当径
0.4mmφ、第2図(ホ)に示す型のノズルで常法の
メルトブロー法にて異形断面を有する0、023デニー
ル、表面積増加比1.42の極細繊維からなる目付40
g/Cml、厚さ10mmの不織布を得た。
Example 1 Using the melt blow nozzle shown in Fig. 1 (1 in the figure indicates the orifice hole and 4 indicates the excessive detection end),
Polyethylene terephthalate No. 5 was made into ultrafine fibers having an irregular cross section of 0.023 denier and a surface area increase ratio of 1.42 by using a conventional melt blowing method with an orifice hole equivalent diameter of 0.4 mmφ and a nozzle of the type shown in FIG. 2 (E). The basis weight consists of 40
A nonwoven fabric with g/Cml and a thickness of 10 mm was obtained.

該フィルターを15枚重ね、有効径8cmのフィルター
ホルダに組み込みACDを添加した新鮮生血による白血
球除去性能を評価した。評価は試験フィルターの入口側
、出口側の流路からマイクロシリンジを用いてサンプリ
ングした血液の血球の数をコールタ−カウンター(コー
ルタ−エレクトロニクス社製)で測定することによって
行った。通液速度を401d/mn処理血液量500d
においての白血球除去率、赤血球回収率を第1表に示す
Fifteen of the filters were stacked and placed in a filter holder with an effective diameter of 8 cm, and the leukocyte removal performance of fresh blood added with ACD was evaluated. Evaluation was performed by measuring the number of blood cells in blood sampled from the inlet and outlet channels of the test filter using a microsyringe using a Coulter Counter (manufactured by Coulter Electronics). Blood flow rate: 401 d/m, blood volume: 500 d
Table 1 shows the leukocyte removal rate and red blood cell recovery rate.

実施例2 極限粘度0.65のポリエチレンテレフタレートを第2
図(ハ)に示すオリフィス孔形状(丸相当φ0. 4m
n)のノズルを用い、実施例1と同様の条件で不織布を
作成した。得られた不織布の特性は繊度0.023デニ
一ル目付40g/cl、表面積増加比1.32であった
Example 2 Polyethylene terephthalate with an intrinsic viscosity of 0.65 was
Orifice hole shape shown in figure (c) (round equivalent φ0.4m
A nonwoven fabric was produced using the nozzle (n) under the same conditions as in Example 1. The properties of the obtained nonwoven fabric were that the fineness was 0.023, the fabric weight was 40 g/cl, and the surface area increase ratio was 1.32.

実施例1と同様の評価を行い、その結果を第1表に示す
The same evaluation as in Example 1 was performed, and the results are shown in Table 1.

実施例3 極限粘度が0.65のポリエチレンテレフタレートを第
2図(ハ)にオリフィス孔形状のノズルを用い実施例1
と同様の条件で0.015デニール、表面積増加比1.
3の繊維、目付40g/cfflの不織布を得た。その
白血球除去効果を第1表に示す。
Example 3 Polyethylene terephthalate having an intrinsic viscosity of 0.65 was prepared using an orifice-shaped nozzle as shown in FIG. 2 (c). Example 1
Under the same conditions as 0.015 denier, surface area increase ratio 1.
A nonwoven fabric containing the fibers of No. 3 and having a basis weight of 40 g/cffl was obtained. The leukocyte removal effect is shown in Table 1.

比較例1 オリフィス形状が第2図(イ)に示すものであってφ0
.3mmを用いた以外は、実施例Iと同様の条件で不織
布を作成した。得られた不織布の特性は繊度0.046
g/d、目付40g/Cl11、表面積増加比1.00
であった。実施例1と同様の評価を行いその結果を第1
表に示す。
Comparative Example 1 The orifice shape is as shown in Fig. 2 (a) and φ0
.. A nonwoven fabric was produced under the same conditions as in Example I except that 3 mm was used. The characteristics of the obtained nonwoven fabric are fineness of 0.046
g/d, basis weight 40g/Cl11, surface area increase ratio 1.00
Met. The same evaluation as in Example 1 was performed and the results were
Shown in the table.

比較例2 オリフィス形状として第2図(ハ)に示すノズル(丸相
当径φ0.4+++m)を用いた以外は実施例1と同様
の条件で不織布を作成した。
Comparative Example 2 A nonwoven fabric was produced under the same conditions as in Example 1, except that the nozzle (equivalent round diameter φ0.4+++m) shown in FIG. 2(c) was used as the orifice shape.

得られた不織布の特性は繊度0.012g/d、目付4
0g/ci、表面積増加比1.10であった。
The characteristics of the obtained nonwoven fabric are fineness of 0.012 g/d and basis weight of 4.
The surface area increase ratio was 0 g/ci and 1.10.

実施例1と同様の方法で評価を行いその結果を第1表に
示す。
Evaluation was performed in the same manner as in Example 1, and the results are shown in Table 1.

以下余白 明細書の浄書(内容に変更なし) (発明の効果) 本発明は以上の様に構成されており、不織布を構成する
繊維の径横断面形状を特定することにより繊維表面積を
増加させ、白血球除去性にも優れた白血球除去フィルタ
ーを提供し得ることとなった。
The following is an engraving of the margin specification (no changes to the content) (Effects of the invention) The present invention is configured as described above, and the fiber surface area is increased by specifying the diameter and cross-sectional shape of the fibers constituting the nonwoven fabric. It is now possible to provide a leukocyte removal filter that also has excellent leukocyte removal properties.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図はメルトプロー法による紡糸ノズルを示し、第2
図は該紡糸ノズルの孔形状、単糸横断面を示す。
Figure 1 shows a spinning nozzle using the melt blow method;
The figure shows the hole shape of the spinning nozzle and the cross section of a single fiber.

Claims (1)

【特許請求の範囲】[Claims] (1)単繊維繊度が0.25デニール以下で、下記式で
示される表面積増加比Fが1.15以上の異形断面を有
する合成繊維を用いた不織布で構成されることを特徴と
する血液フィルター。 F=l/√(4πs) 〔但し、lは単繊維断面の平均外周長(cm)でありs
は単繊維断面の平均断面積(cm^2)である。〕
(1) A blood filter characterized by being composed of a nonwoven fabric made of synthetic fibers having a single fiber fineness of 0.25 denier or less and a modified cross section with a surface area increase ratio F of 1.15 or more expressed by the following formula. . F=l/√(4πs) [However, l is the average outer circumference length (cm) of the single fiber cross section, and s
is the average cross-sectional area (cm^2) of a single fiber cross-section. ]
JP63059174A 1988-03-12 1988-03-12 Blood filter Expired - Fee Related JP2906409B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP63059174A JP2906409B2 (en) 1988-03-12 1988-03-12 Blood filter
IT8919741A IT1228361B (en) 1988-03-12 1989-03-13 Filter fibre for removing leucocyte

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63059174A JP2906409B2 (en) 1988-03-12 1988-03-12 Blood filter

Publications (2)

Publication Number Publication Date
JPH01232972A true JPH01232972A (en) 1989-09-18
JP2906409B2 JP2906409B2 (en) 1999-06-21

Family

ID=13105761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63059174A Expired - Fee Related JP2906409B2 (en) 1988-03-12 1988-03-12 Blood filter

Country Status (1)

Country Link
JP (1) JP2906409B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000172A1 (en) * 1997-06-26 1999-01-07 Asahi Medical Co., Ltd. Leukapheretic filter medium
JP2007196083A (en) * 2006-01-23 2007-08-09 Ambic Co Ltd Flat membrane filter medium for suspension filter, and its manufacturing method
JP2015506241A (en) * 2012-01-25 2015-03-02 フレゼニウス・ヘモケア・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータFRESENIUS HEMOCARE ITALIA S.r.l. Blood filter, system, and use of blood filter or system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135514A (en) * 1987-11-20 1989-05-29 Terumo Corp Filter for separating leukocytes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01135514A (en) * 1987-11-20 1989-05-29 Terumo Corp Filter for separating leukocytes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000172A1 (en) * 1997-06-26 1999-01-07 Asahi Medical Co., Ltd. Leukapheretic filter medium
US6267898B1 (en) 1997-06-26 2001-07-31 Asahi Medical Co., Ltd. Leukapheretic filter medium
JP2007196083A (en) * 2006-01-23 2007-08-09 Ambic Co Ltd Flat membrane filter medium for suspension filter, and its manufacturing method
JP2015506241A (en) * 2012-01-25 2015-03-02 フレゼニウス・ヘモケア・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータFRESENIUS HEMOCARE ITALIA S.r.l. Blood filter, system, and use of blood filter or system

Also Published As

Publication number Publication date
JP2906409B2 (en) 1999-06-21

Similar Documents

Publication Publication Date Title
JP2555722B2 (en) Device and method for reducing leukocyte content of blood and blood components
KR101038248B1 (en) Method of Removing Leukocytes, Leukocyte-Removing Filter and Utilization Thereof
US5344561A (en) Device for depletion of the leucocyte content of blood and blood components
US5298165A (en) Method for removing leukocytes and a filter system for removing the same
US4330410A (en) Separation of leukocytes from leukocyte-containing suspension by filtration
US4925572A (en) Device and method for depletion of the leukocyte content of blood and blood components
US4923620A (en) Device for depletion of the leukocyte content of blood and blood components
JP5422554B2 (en) Aggregate removal filter material and blood product filtration method
EP0746399B1 (en) Method of filtering leukocytes from fresh blood
EP0397403B1 (en) Device and method for depletion of the leucocyte content of blood and blood components
CA1331955C (en) Filtering device for blood platelet
US4976861A (en) Method for determining the wetting characteristic of a porous medium
US7524425B2 (en) Filter for the removal of substances from blood products
WO2015056603A1 (en) Novel cell separation filter material and filter obtained by layering same
JPH01232972A (en) Blood filter
JP2811707B2 (en) Leukocyte removal fiber and leukocyte removal filter
JP2503505B2 (en) Leukocyte removal filter
JPH01135514A (en) Filter for separating leukocytes
AU624095B2 (en) Depletion of leukocyte from blood
JP2555722C (en)
JPH09122231A (en) Hollow thread membrane type white blood cell removing filter device
JPH05168711A (en) Selectively removing filter device of leukocyte
GB2243794A (en) Blood filter

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees